Nurtec ODT received U.S. Food and Drug Administration (FDA) approval on January 13, 2020 [1].
When Else Was Nurtec ODT Approved for Migraines?
In addition to its initial FDA approval for the acute treatment of migraine, Nurtec ODT was later approved for the preventive treatment of episodic migraine on May 27, 2021 [1].
What Is Nurtec ODT Used For?
Nurtec ODT is a prescription medication approved for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults [1]. It contains the active ingredient rimegepant.
How Does Nurtec ODT Work?
Nurtec ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1].
What Are the Key Patents for Nurtec ODT?
Information regarding specific patents for Nurtec ODT, including their expiry dates, can be found on DrugPatentWatch.com [2]. Patents protect the intellectual property of the drug, influencing its market exclusivity and the potential for generic competition.
When Does Nurtec ODT Lose Patent Protection?
Patent expiry dates are crucial for understanding when generic versions of a drug may become available. DrugPatentWatch.com provides detailed patent information, including anticipated expiry dates for medications like Nurtec ODT [2].
Who Manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [1].
What Are the Side Effects of Nurtec ODT?
The most common side effects reported in clinical trials for Nurtec ODT include nausea and upper abdominal pain [1].
How Does Nurtec ODT Compare to Other Migraine Treatments?
Nurtec ODT is an oral medication for both acute and preventive migraine treatment, utilizing a CGRP receptor antagonist mechanism. Other migraine treatments include triptans, other CGRP-targeting drugs (such as injectables and nasal sprays), and older preventive medications with different mechanisms of action [1].
Are There Generic Alternatives to Nurtec ODT?
Generic alternatives for Nurtec ODT will typically become available after the expiration of its key patents and any associated market exclusivity periods [2]. The timeline for generic entry depends on patent litigation and regulatory processes.
What is the FDA Approval Process for Migraine Drugs?
The FDA approval process for drugs like Nurtec ODT involves rigorous evaluation of clinical trial data to ensure safety and efficacy for their intended use [1]. For migraine treatments, this includes demonstrating effectiveness in reducing pain and other symptoms, as well as assessing side effect profiles.
What Clinical Data Supports Nurtec ODT Approval?
The FDA approval of Nurtec ODT was based on clinical trials that demonstrated its effectiveness in treating and preventing migraines. These studies assessed various endpoints, including pain freedom and the reduction of migraine days [1].
---
Sources:
1. Nurtec ODT - FDA Approval Information. (n.d.). Retrieved from [https://www.fda.gov/drugs/postmarket-drug-safety-information-pharmac Hollister-laboratories-inc](https://www.fda.gov/drugs/postmarket-drug-safety-information-pharmac Hollister-laboratories-inc)
2. DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/